USPTO serial 79326219
APEXP
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 28, 2023
- Examiner
- MESSICK, TABITHA LEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with APEXP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John G. Tutunjian
John G. Tutunjian Tutunjian & Bitetto, P.C.401 Broadhollow RoadSutie 402Melville, NY 11747Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable software for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software platforms for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software using artificial intelligence for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software platforms using artificial intelligence for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria | ACTIVE | — |
| 042 | Software as a service (SaaS) services featuring software for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; software as a service (SaaS) services featuring artificial intelligence software for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; platform as a service (PaaS) services featuring software platforms for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; platform as a service (PaaS) services featuring software platforms using artificial intelligence for the research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; biomedical research services; scientific research for medical purposes in the field of infectious diseases and diseases caused by bacteria; research and development of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; conducting clinical trials for others of pharmaceutical compositions, pharmaceutical products, diagnostic reagents, antibiotics, biomarkers, enzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TELUM THERAPEUTICS S.L.
- Other trademarks owned by TELUM THERAPEUTICS S.L.
- Other trademarks owned by TELUM THERAPEUTICS S.L.
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named APEXP
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 7, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 18, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 18, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 28, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 28, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 28, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 24, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 10, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 10, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 4, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 4, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 21, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 2, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 17, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 16, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 16, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 19, 2022 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Oct 6, 2022 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Oct 6, 2022 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Aug 23, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 29, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 29, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 3, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 2, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 28, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 29, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 23, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 19, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 18, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |